Skip to main content

A pharmacogenomic approach to Alzheimer's disease

Buy Article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

Abstract:

Single nucleotide polymorphisms (susceptibility genetics) and genomic point mutations (mendelian genetics) can be used in Alzheimer's disease (AD) for diagnostic, predictive and therapeutic purposes. Using a matrix genetic model, including APOE, PS1 and PS2 allelic variants, we have studied the distribution of 36 different genotypes in the AD population (N=479) and the genotype-related cognitive response to a multifactorial therapy in AD patients with mild-to-moderate dementia. The 10 most frequent AD genotypes are the following: 1) E33P112P2+ (17.75%), 2) E33P112P2- (15.55%), 3) E33P111P2+ (10.85%), 4) E34P112P2+ (9.60%), 5) E34P112P2- (7.56%), 6) E33P111P2- (7.10%), 7) E34P111P2+ (4.80%), 8) E33P122P2+ (4.38%), 9) E34P111P2- (4.18%), and 10) E34P122P2+ (3.55%). APOE-4/4-related genotypes represent less than 3% in the following order: E44P112P2+> E44P111P2+=E44P111P2->E44P112P2+>E44P122P2+= E44P122P2-. Multifactorial therapy with CDP-choline (1000 mg/day)+piracetam (2400 mg/day)+anapsos (360 mg/day) did improve mental performance during the first 6–15 months in a genotype-specific fashion. The best responders in the APOE series were patients with APOE-3/4 genotype (r=+0.013), while the worst responders were APOE-4/4 patients (r=-0.93). PS1-related genotypes responded in a similar manner; and patients with a defective PS2 gene exon 5 (PS2+) always showed a poorer therapeutic response than PS2- patients. All these data suggest that the therapeutic outcome in AD exhibits a genotype-specific pattern, and that a pharmacogenomic approach to AD might be a valuable strategy for drug development and monitoring.

Keywords: AD-related genes; Alzheimer's disease; CDP-choline; anapsos/calagualine; multifactorial therapy; mutational genetics; pharmacogenomics; piracetam; susceptibility genetics

Document Type: Original Article

Affiliations: EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15,166-Bergondo, La Coruña, Spain

Publication date: December 1, 2000

mksg/ane/2000/00000102/A176s176/art00002
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more